Source content
FAA Guide for Aviation Medical Examiners · Version 10/28/2026 · page 284
CACI - Arthritis Worksheet (Updated 04/29/2026)
To determine the applicant’s eligibility for certification, the AME must review a current, detailed Clinical
Progress Note generated from a clinic visit with the treating physician or specialist no more than 90 days
prior to the AME exam. If the applicant meets ALL the acceptable certification criteria listed below, the
AME can issue. Applicants for first- or second- class must provide this information annually; applicants for
third-class must provide the information with each required exam.
AME MUST REVIEW ACCEPTABLE CERTIFICATION CRITERIA
Treating physician finds the condition [ ] Yes
stable on current regimen and no
changes recommended
Symptoms [ ] None or mild to moderate symptoms with no significant limitations to range of
motion, lifestyle, or activities
Cause of Arthritis Acceptable causes are limited to:
[ ] Osteoarthritis* and/or
*Osteoarthritis - see Arthritis
[ ] Autoimmune to include only the following: rheumatoid (limited to joint),
Disposition Table
psoriatic, or ankylosing spondylitis
CACI may not be required.
Acceptable Medications [ ] One or more of the following with or without routine NSAID use:
• Oral steroid prednisone 20 mg/day equivalent or less
(see steroid conversion calculator)
• NSAID (routine use)
• azathioprine (Imuran)
KEY:
• methotrexate (Trexall)
• sulfasalazine (Azulfidine)
Interleukin Inhibitors (IL)
• Hydroxychloroquine (HCQ)/Chloroquine (Plaquenil/Aralen) see status
report requirement below**
Janus Associated Kinase
• Any singe medication listed below after a 2-week ground trial and:
Inhibitor (JAK)
No post-dose observation time:
o PDE4: apremilast (Otezla)
Monoclonal Antibody, Anti-CD20
o JAK: baricitinib (Olumiant); tofacitinib (Xeljanz); upadacitinib
(CD20)
(Rinvoq)
4-hour post-dose observation time:
Phosphodiesterase-4 Enzyme
o TNF: adalimumab (Humira and all biosimilars), certolizumab
Inhibitor (PDE4) (Cimzia), etanercept (Enbrel), golimumab (Simponi)
o IL: anakinra (Kineret), guselkumab (Tremfya), ixekizumab
Selective T-Cell Costimulation (Taltz), risankizumab (Skyrizi), sarilumab (Kevzara),
Blocker (T-Cell) secukinumab (Cosentyx), tocilizumab (Actemra),
ustekinumab (Stelara)
Tumor necrosis factor inhibitors Other post-dose observation time:
o 72-hour rituximab (Rituxan) 72-hour - CD20
(TNF)
o 24 hours: infliximab (Inflect, Remicade, Renflexis) - TNF
o 24 hours: abatacept (Orencia) – T-Cell
** STATUS SUMMARY is required if [ ] Hydroxychloroquine (HCQ)/ Chloroquine (CQ) Status Summary
Hydroxychloroquine (HCQ)/ (Plaquenil/Aralen) is favorable and no concerns
Chloroquine (CQ) (Plaquenil/Aralen) OR
is used. [ ] N/A (NOT taking hydroxychloroquine/chloroquine [Plaquenil/Aralen])
AME MUST NOTE in Block 60 one of the following:
[ ] CACI qualified arthritis. (Documents do not need to be submitted to the FAA.)
[ ] Has current OR previous SI/AASI but now CACI qualified arthritis.
[ ] NOT CACI qualified arthritis. I have deferred. (Submit supporting documents.)
FAA Guide for Aviation Medical Examiners, Version 10/28/2026, page 284. AME Copilot is an independent reference tool, not affiliated with or endorsed by the FAA. The FAA AME Guide is the authoritative source.